205 related articles for article (PubMed ID: 36859773)
1. High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions.
Lourenço AL; Chuo SW; Bohn MF; Hann B; Khan S; Yevalekar N; Patel N; Yang T; Xu L; Lv D; Drakas R; Lively S; Craik CS
MAbs; 2023; 15(1):2184197. PubMed ID: 36859773
[TBL] [Abstract][Full Text] [Related]
2. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.
LeBeau AM; Duriseti S; Murphy ST; Pepin F; Hann B; Gray JW; VanBrocklin HF; Craik CS
Cancer Res; 2013 Apr; 73(7):2070-81. PubMed ID: 23400595
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
[TBL] [Abstract][Full Text] [Related]
4. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
5. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
6. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Jo M; Takimoto S; Montel V; Gonias SL
Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
8. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
10. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
11. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
[TBL] [Abstract][Full Text] [Related]
12. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
Chavakis T; Kanse SM; May AE; Preissner KT
Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
[TBL] [Abstract][Full Text] [Related]
13. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
LeBeau AM; Sevillano N; King ML; Duriseti S; Murphy ST; Craik CS; Murphy LL; VanBrocklin HF
Theranostics; 2014; 4(3):267-79. PubMed ID: 24505235
[TBL] [Abstract][Full Text] [Related]
14. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
16. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.
Qin L; Wang L; Zhang J; Zhou H; Yang Z; Wang Y; Cai W; Wen F; Jiang X; Zhang T; Ye H; Long B; Qin J; Shi W; Guan X; Yu Z; Yang J; Wang Q; Jiao Z
Sci Adv; 2022 May; 8(21):eabn3774. PubMed ID: 35613265
[TBL] [Abstract][Full Text] [Related]
18. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells.
Jo M; Eastman BM; Webb DL; Stoletov K; Klemke R; Gonias SL
Cancer Res; 2010 Nov; 70(21):8948-58. PubMed ID: 20940399
[TBL] [Abstract][Full Text] [Related]
19. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
[TBL] [Abstract][Full Text] [Related]
20. Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Smaradhania N; Rahman S; Ardi Syamsu S; Prihantono P
Breast Dis; 2021; 40(S1):S1-S7. PubMed ID: 34057113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
